Faculty Bibliography
Searched for:
school:SOM
Department/Unit:Population Health
Total Results:
12703
Promoting hearing assistance for social engagement (Phase) in los angeles communities [Meeting Abstract]
Background: Hearing loss compounds social isolation. We tested acceptability and benefit of simple hearing assistance devices- Personal Amplifiers (PAs)-provided to older people with hearing loss and risk for social isolation, loneliness and depression.
Method(s): We conducted a pre-post pilot trial with 1-and 2-month follow-up of residents of six low-income senior apartment buildings in Los Angeles (n = 74) who had hearing difficulties, based on either (A) >= 10 (range 0-40) on the Hearing Handicap Inventory - Survey; or (B) hearing loss based on a clinically validated audiological iPad assessment (SHOEBOXTM) with surveys at 0, 1 and 2 months using 4 instruments: (1) Social Isolation Score (SIS); (2) Patient Health Questionnaire (PHQ-9); (3) Sense of Social Support scale; and (4) DG Loneliness Scale. We assessed PA use and perceived benefit using the International Outcome Inventory for Alternative Interventions (IOI-AI).
Result(s): Baseline characteristics and degree of hearing problems did not vary significantly among 74 initial enrollees. Fortytwo residents completed 1-and 2-month surveys. Mean age was 78.2 years; 64% were women; 83% scored >=10 on HHI-S and 83% met SHOEBOX criteria for hearing loss. At baseline, 31% met SIS criteria for social isolation (>=2; mean=1.0; SD:0.98); 41% met DG criteria for loneliness; and 19% had low social support. Mean PHQ-9 was 7.0, (SD:5.3); 26% had moderate to severe mood symptoms. At 2-month follow up, 87% reported PA use of >= one hour/day, and 76% indicated that the device changed life enjoyment 'quite a lot.' Psychosocial measures improved over time.
Conclusion(s): In a vulnerable older population with hearing difficulties, simple PAs were enthusiastically received and may have improved social functioning and mood. Further work with stronger study designs is needed to shed more light on the effectiveness of this approach
Method(s): We conducted a pre-post pilot trial with 1-and 2-month follow-up of residents of six low-income senior apartment buildings in Los Angeles (n = 74) who had hearing difficulties, based on either (A) >= 10 (range 0-40) on the Hearing Handicap Inventory - Survey; or (B) hearing loss based on a clinically validated audiological iPad assessment (SHOEBOXTM) with surveys at 0, 1 and 2 months using 4 instruments: (1) Social Isolation Score (SIS); (2) Patient Health Questionnaire (PHQ-9); (3) Sense of Social Support scale; and (4) DG Loneliness Scale. We assessed PA use and perceived benefit using the International Outcome Inventory for Alternative Interventions (IOI-AI).
Result(s): Baseline characteristics and degree of hearing problems did not vary significantly among 74 initial enrollees. Fortytwo residents completed 1-and 2-month surveys. Mean age was 78.2 years; 64% were women; 83% scored >=10 on HHI-S and 83% met SHOEBOX criteria for hearing loss. At baseline, 31% met SIS criteria for social isolation (>=2; mean=1.0; SD:0.98); 41% met DG criteria for loneliness; and 19% had low social support. Mean PHQ-9 was 7.0, (SD:5.3); 26% had moderate to severe mood symptoms. At 2-month follow up, 87% reported PA use of >= one hour/day, and 76% indicated that the device changed life enjoyment 'quite a lot.' Psychosocial measures improved over time.
Conclusion(s): In a vulnerable older population with hearing difficulties, simple PAs were enthusiastically received and may have improved social functioning and mood. Further work with stronger study designs is needed to shed more light on the effectiveness of this approach
EMBASE:634826887
ISSN: 1532-5415
CID: 4870562
The HEAR-VA Pilot Study: Hearing Assistance Provided to Older Adults in the Emergency Department
BACKGROUND/OBJECTIVES/OBJECTIVE:Poor communication is a barrier to care for people with hearing loss. We assessed the feasibility and potential benefit of providing a simple hearing assistance device during an emergency department (ED) visit, for people who reported difficulty hearing. DESIGN/METHODS:Randomized controlled pilot study. SETTING/METHODS:The ED of New York Harbor Manhattan Veterans Administration Medical Center. PARTICIPANTS/METHODS:One hundred and thirty-three Veterans aged 60 and older, presenting to the ED, likely to be discharged to home, who either (1) said that they had difficulty hearing, or (2) scored 10 or greater (range 0-40) on the Hearing Handicap Inventory-Survey (HHI-S). INTERVENTION/METHODS:Subjects were randomized (1:1), and intervention subjects received a personal amplifier (PA; Williams Sound Pocketalker 2.0) for use during their ED visit. MEASUREMENTS/METHODS:Three survey instruments: (1) six-item Hearing and Understanding Questionnaire (HUQ); (2) three-item Care Transitions Measure; and (3) three-item Patient Understanding of Discharge Information. Post-ED visit phone calls to assess ED returns. RESULTS:Of the 133 subjects, 98.3% were male; mean age was 76.4 years (standard deviation (SD) = 9.2). Mean HHI-S score was 19.2 (SD = 8.3). Across all HUQ items, intervention subjects reported better in-ED experience than controls. Seventy-five percent of intervention subjects agreed or strongly agreed that ability to understand what was said was without effort versus 56% for controls. Seventy-five percent of intervention subjects versus 36% of controls said clinicians provided them with an explanation about presenting problems. Three percent of intervention subjects had an ED revisit within 3 days compared with 9.0% controls. CONCLUSION/CONCLUSIONS:Veterans with hearing difficulties reported improved in-ED experiences with use of PAs, and were less likely to return to the ED within 3 days. PAs may be an important adjunct to older patient ED care but require validation in a larger more definitive randomized controlled trial.
PMID: 33576037
ISSN: 1532-5415
CID: 4780132
A pilot study on the use of cfinancial incentives for smoking cessation in cognitively impaired patients [Meeting Abstract]
Background: Modifiable risk factors contribute to not only the development, but also the progression of dementia. Smoking is a relevant risk factor, and although relatively few people with dementia are smokers, smoking cessation can positively impact both patient quality of life and healthcare system costs. Notably, these patients also have an increased risk of smoking-related accidents and fire hazards. Despite this, smoking cessation is not routinely addressed in dementia care, and there are no reported smoking cessation interventions specifically for dementia patients. Therefore, we are developing and pilot testing an approach to help smokers with cognitive impairment quit smoking.
Method(s): We are conducting a study of financial incentives to increase smoking cessation among patients hospitalized at 2 public safety net hospitals. We received an NIA supplement to include cognitively impaired patients, who were originally excluded from the study. We will begin by investigating how to adapt smoking cessation interventions for patients with cognitive impairment by conducting structured interviews with 15 current smokers, who have a diagnosis of cognitive impairment or dementia, and their caregivers. Based on analysis of interview transcripts, we will adapt both the intervention arms and our smoking cessation counseling manuals. We will then test these modifications on 6 patients with cognitive impairment and adapt them further. For the FIESTA II pilot study, we will recruit 50 participants, who will be randomized to standard therapy or one of the two financial incentive arms. Standard therapy includes the use of NRT, medication, and individual counseling targeting smoking cessation. The two financial incentive arms will be either outcome-based or goalbased, where patients are compensated for successful smoking abstinence or utilization of counseling and quitting aids, respectively. Our outcomes for the pilot study are use of smoking cessation treatments, quit attempts and abstinence.
Result(s): We are currently conducting the initial qualitative interviews.
Conclusion(s): We will discuss the results of the pilot study and their implications for geriatric practice
Method(s): We are conducting a study of financial incentives to increase smoking cessation among patients hospitalized at 2 public safety net hospitals. We received an NIA supplement to include cognitively impaired patients, who were originally excluded from the study. We will begin by investigating how to adapt smoking cessation interventions for patients with cognitive impairment by conducting structured interviews with 15 current smokers, who have a diagnosis of cognitive impairment or dementia, and their caregivers. Based on analysis of interview transcripts, we will adapt both the intervention arms and our smoking cessation counseling manuals. We will then test these modifications on 6 patients with cognitive impairment and adapt them further. For the FIESTA II pilot study, we will recruit 50 participants, who will be randomized to standard therapy or one of the two financial incentive arms. Standard therapy includes the use of NRT, medication, and individual counseling targeting smoking cessation. The two financial incentive arms will be either outcome-based or goalbased, where patients are compensated for successful smoking abstinence or utilization of counseling and quitting aids, respectively. Our outcomes for the pilot study are use of smoking cessation treatments, quit attempts and abstinence.
Result(s): We are currently conducting the initial qualitative interviews.
Conclusion(s): We will discuss the results of the pilot study and their implications for geriatric practice
EMBASE:634827014
ISSN: 1532-5415
CID: 4870552
Sex-dependent associations of maternal androgen levels with offspring BMI and weight trajectory from birth to early childhood
CONTEXT/BACKGROUND:In preclinical studies, high androgen levels during pregnancy are associated with low birth weight and rapid postnatal weight gain in the offspring. However, human data linking prenatal androgens with birth weight and early life weight gain in the offspring are scarce. DESIGN/METHODS:We evaluated 516 mother-child pairs enrolled in the New England birth cohorts of the Collaborative Perinatal Project (1959-1966). We assayed androgen bioactivity in maternal sera during third-trimester using a receptor-mediated luciferase expression bioassay. Age and sex-specific BMI Z-scores (BMIz), defined using established standards, were assessed at birth, 4 months, 1 year, 4 years, and 7 years. We used linear mixed models to evaluate the relation of maternal androgens with childhood BMIz overall and by sex. We examined the association of maternal androgens with fetal growth restriction. The association of weight trajectories with maternal androgens was examined using multinomial logistic regression. RESULTS:Higher maternal androgen levels associated with lower BMIz at birth (β = - 0.39, 95% CI: - 0.73, - 0.06); this relation was sex-dependent, such that maternal androgens significantly associated with BMIz at birth in girls alone (β = - 0.72, 95% CI: - 1.40, - 0.04). The relation of maternal androgens with fetal growth restriction revealed dose threshold effects that differed by sex. There was no significant association between maternal androgens and weight trajectory overall. However, we found a significant sex interaction (p = 0.01); higher maternal androgen levels associated with accelerated catch-up growth in boys (aOR = 2.14, 95% CI: 1.14, 4.03). CONCLUSION/CONCLUSIONS:Our findings provide evidence that maternal androgens may have differential effects on the programming of intrauterine growth and postnatal weight gain depending on fetal sex.
PMCID:7873156
PMID: 32776198
ISSN: 1720-8386
CID: 5037462
High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults
BACKGROUND/OBJECTIVES:Traditional cardiovascular risk factors are less predictive in older age. High-sensitivity cardiac troponin I (hs-cTnI) is a marker of subclinical cardiomyocyte damage associated with cardiovascular risk in middle-aged adults. We hypothesized hs-cTnI would be indicative of mortality and cardiovascular risk beyond traditional cardiovascular risk factors in older adults and may be more discriminatory compared to hs-troponin T (hs-cTnT). DESIGN:Prospective cohort study. SETTING:Population-based Atherosclerosis Risk in Communities (ARIC) Study. PARTICIPANTS:We included 5,876 ARIC participants at Visit 5 (2011-2013). OUTCOMES AND MEASURES:We used Cox regression for the association of hs-cTnI categories (women: <4, 4-<10, ≥10 ng/ml; men: <6, 6-<12, ≥12 ng/ml, prevalent cardiovascular disease (CVD)) with mortality and incident CVD (atherosclerotic CVD [ASCVD]: coronary heart disease or stroke, or heart failure). RESULTS:Participants were ages 66 to 90, 23% black, 42% male, and 24% had prevalent CVD. There were 1,053 (321 CVD) deaths (median follow-up 6.3 years). Participants with elevated hs-cTnI and no CVD (7% of participants) had mortality risk similar to those with a history of CVD (55.6 vs 55.7 deaths/1,000 person-years, P = .99). After adjustment, elevated hs-cTnI and no CVD (hazard ratio (HR) = 2.38, 95% confidence interval (CI) = 1.85-3.06) and prevalent CVD (HR = 2.21, 95% CI = 1.90-2.57) remained associated with mortality, compared to low hs-cTnI and no CVD. Elevated hs-cTnI was independently associated with incident CVD (HR = 3.41, 95% CI = 2.58-4.51), ASCVD (HR = 2.02, 95% CI = 1.36-2.98), and heart failure (HR = 6.16, 95% CI = 4.24-8.95). The addition of hs-cTnI significantly improved C-statistics for all outcomes and added greater discrimination than hs-cTnT for cardiovascular mortality and incident heart failure. CONCLUSIONS:Hs-cTnI improves mortality and CVD risk stratification in older adults beyond traditional risk factors and improved model discrimination more than hs-cTnT for certain outcomes. Elevated hs-cTnI without CVD identifies a high-risk group with comparable mortality risk as those with a history of clinical CVD.
PMCID:8049956
PMID: 33150614
ISSN: 1532-5415
CID: 5585932
Updated process for American Headache Society Guidelines [Editorial]
PMID: 33891346
ISSN: 1526-4610
CID: 4889152
Projected All-Cause Deaths Attributable to COVID-19-Related Unemployment in the United States
PMCID:7958047
PMID: 33600244
ISSN: 1541-0048
CID: 5031472
Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline
Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.
PMID: 33137338
ISSN: 1523-1755
CID: 5585922
Longitudinal predictors of male sexual partner risk among Black and Latina women in their late thirties: ethnic/racial identity commitment as a protective factor
This study aimed to investigate predictors of male sexual partner risk among Latinas and Black women in their late thirties. We used multiple regression analysis to examine factors associated with male sexual partner risk among 296 women who participated in two waves of the Harlem Longitudinal Development Study (New York, 2011-2013 and 2014-2016). Women who experienced childhood sexual abuse had higher risk partners than those who did not [b = 0.16, 95% confidence interval (CI) = 0.06, 0.28]. Earlier marijuana use was a risk factor for partner risk in the late thirties (b = 0.12, 95% CI = 0.04, 0.27). Higher levels of ethnic/racial identity commitment mitigated this risk (b = - 0.15, 95% CI = - 0.26, - 0.04). Ethnic/racial identity commitment can be protective against male sexual partner risk among Latina and Black women who use marijuana. Further research should explore the protective role of different dimensions of ethnic/racial identity against sexually transmitted infections, including HIV.
PMID: 32965619
ISSN: 1573-3521
CID: 4605762
Envisioning a mental health science to empower vulnerable women, children and youth [Letter]
PMCID:8039544
PMID: 33774329
ISSN: 2352-3964
CID: 5831202
